Clinical usefulness of procalcitonin and creactive protein as outcome predictors in critically Ill patients with severe sepsis and septic shock

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  Ryu, Jeong Am ^a   Yang, Jeong Hoon ^a   Lee, Daesang ^a   Park, Chi Min ^a   Suh, Gee Young ^a   Jeon, Kyeongman ^a   Cho, Joongbum ^a   Young Baek, Sun ^a   Carriere, Keumhee C ^b   Chung, Chi Ryang ^a  

^a Samsung Medical Center   (South Korea)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; PROCALCITONIN; CALCA PROTEIN, HUMAN; CALCITONIN; CALCITONIN GENE RELATED PEPTIDE; PROTEIN PRECURSOR;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; COMORBIDITY; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DISEASE SEVERITY; FEMALE; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTIVE VALUE; RETROSPECTIVE STUDY; SEPSIS; SEPTIC SHOCK; SEX DIFFERENCE; SURVIVAL PREDICTION; TREATMENT FAILURE; BLOOD; CLINICAL TRIAL; CRITICAL ILLNESS; DISEASE FREE SURVIVAL; METABOLISM; MICROBIOLOGY; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SHOCK, SEPTIC; SURVIVAL RATE;

AGED; C-REACTIVE PROTEIN; CALCITONIN; CALCITONIN GENE-RELATED PEPTIDE; CRITICAL ILLNESS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROTEIN PRECURSORS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SHOCK, SEPTIC; SURVIVAL RATE;

EID: 84960381810     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0138150     Document Type: Article

References (31)

1. Garnacho-Montero J, Huici-Moreno MJ, Gutierrez-Pizarraya A, Lopez I, Marquez-Vacaro JA, Macher H, et al. Prognostic and diagnostic value of eosinopenia, C-reactive protein, procalcitonin, and circulating cell-free DNA in critically ill patients admitted with suspicion of sepsis. Crit Care. 2014; 18: R116. doi: 10.1186/cc13908 PMID: 24903083
2. Jensen JU, Heslet L, Jensen TH, Espersen K, Steffensen P, Tvede M. Procalcitonin increase in early identification of critically ill patients at high risk of mortality. Crit Care Med. 2006; 34: 2596-2602. PMID: 16915118
3. Kibe S, Adams K, Barlow G. Diagnostic and prognostic biomarkers of sepsis in critical care. J Antimicrob Chemother. 2011; 66 Suppl 2: ii33-40. doi: 10.1093/jac/dkq523 PMID: 21398306
4. Clec'h C, Ferriere F, Karoubi P, Fosse JP, Cupa M, Hoang P, et al. Diagnostic and prognostic value of procalcitonin in patients with septic shock. Crit Care Med. 2004; 32: 1166-1169. PMID: 15190968
5. Ruiz-Alvarez MJ, Garcia-Valdecasas S, De Pablo R, Sanchez Garcia M, Coca C, Groeneveld TW, et al. Diagnostic efficacy and prognostic value of serum procalcitonin concentration in patients with suspected sepsis. J Intensive Care Med. 2009; 24: 63-71. doi: 10.1177/0885066608327095 PMID: 19054806
6. Hoeboer SH, Groeneveld AB. Changes in circulating procalcitonin versus C-reactive protein in predicting evolution of infectious disease in febrile, critically ill patients. PLoS One. 2013; 8: e65564. doi: 10.1371/journal.pone.0065564 PMID: 23762396
7. Karlsson S, Heikkinen M, Pettila V, Alila S, Vaisanen S, Pulkki K, et al. Predictive value of procalcitonin decrease in patients with severe sepsis: a prospective observational study. Crit Care. 2010; 14: R205. doi: 10.1186/cc9327 PMID: 21078153
8. Mat Nor MB, Md Ralib A. Procalcitonin clearance for early prediction of survival in critically ill patients with severe sepsis. Crit Care Res Pract. 2014; 2014: 819034. doi: 10.1155/2014/819034 PMID: 24719759
9. Seligman R, Meisner M, Lisboa TC, Hertz FT, Filippin TB, Fachel JM, et al. Decreases in procalcitonin and C-reactive protein are strong predictors of survival in ventilator-associated pneumonia. Crit Care. 2006; 10: R125. PMID: 16956405
10. Ruiz-Rodriguez JC, Caballero J, Ruiz-Sanmartin A, Ribas VJ, Perez M, Boveda JL, et al. Usefulness of procalcitonin clearance as a prognostic biomarker in septic shock. A prospective pilot study. Med Intensiva. 2012; 36: 475-480. doi: 10.1016/j.medin.2011.11.024 PMID: 22257436
11. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013; 41: 580-637. doi: 10.1097/CCM.0b013e31827e83af PMID: 23353941
12. Jimeno A, Garcia-Velasco A, del Val O, Gonzalez-Billalabeitia E, Hernando S, Hernandez R, et al. Assessment of procalcitonin as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia. Cancer. 2004; 100: 2462-2469. PMID: 15160353
13. Liu X, Wang DF, Fang Y, Ye WF, Liu S, Lou N. Initial procalcitonin level predicts infection and its outcome in patients with non-Hodgkin lymphoma with febrile neutropenia. Leuk Lymphoma. 2015; 56: 85-91. doi: 10.3109/10428194.2014.911864 PMID: 24707944
14. Kumpers P, Hafer C, Lukasz A, Lichtinghagen R, Brand K, Fliser D, et al. Serum neutrophil gelatinaseassociated lipocalin at inception of renal replacement therapy predicts survival in critically ill patients with acute kidney injury. Crit Care. 2010; 14: R9. doi: 10.1186/cc8861 PMID: 20122150
15. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992; 20: 864-874. PMID: 1597042
16. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003; 31: 1250-1256. PMID: 12682500
17. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011; 52: e56-93. doi: 10.1093/cid/cir073 PMID: 21258094
18. Darmon M, Thiery G, Ciroldi M, de Miranda S, Galicier L, Raffoux E, et al. Intensive care in patients with newly diagnosed malignancies and a need for cancer chemotherapy. Crit Care Med. 2005; 33: 2488-2493. PMID: 16276171
19. Benoit DD, Depuydt PO, Vandewoude KH, Offner FC, Boterberg T, De Cock CA, et al. Outcome in severely ill patients with hematological malignancies who received intravenous chemotherapy in the intensive care unit. Intensive Care Med. 2006; 32: 93-99. PMID: 16308681
20. Song JU, Suh GY, Park HY, Lim SY, Han SG, Kang YR, et al. Early intervention on the outcomes in critically ill cancer patients admitted to intensive care units. Intensive Care Med. 2012; 38: 1505-1513. doi: 10.1007/s00134-012-2594-0 PMID: 22592633
21. Yoo H, Suh GY, Jeong BH, Lim SY, Chung MP, Kwon OJ, et al. Etiologies, diagnostic strategies, and outcomes of diffuse pulmonary infiltrates causing acute respiratory failure in cancer patients: a retrospective observational study. Crit Care. 2013; 17: R150. doi: 10.1186/cc12829 PMID: 23880212
22. Song JU, Suh GY, Chung MP, Kim H, Kwon OJ, Jung CW, et al. Risk factors to predict outcome in critically ill cancer patients receiving chemotherapy in the intensive care unit. Support Care Cancer. 2011; 19: 491-495. doi: 10.1007/s00520-010-0841-x PMID: 20229331
23. Navi BB, Reichman JS, Berlin D, Reiner AS, Panageas KS, Segal AZ, et al. Intracerebral and subarachnoid hemorrhage in patients with cancer. Neurology. 2010; 74: 494-501. doi: 10.1212/WNL. 0b013e3181cef837 PMID: 20142616
24. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44:837-845 PMID: 3203132
25. Povoa P, Almeida E, Moreira P, Fernandes A, Mealha R, Aragao A, et al. C-reactive protein as an indicator of sepsis. Intensive Care Med. 1998; 24: 1052-1056. PMID: 9840239
26. Yentis SM, Soni N, Sheldon J. C-reactive protein as an indicator of resolution of sepsis in the intensive care unit. Intensive Care Med. 1995; 21: 602-605. PMID: 7593905
27. Debiane L, Hachem RY, Al Wohoush I, Shomali W, Bahu RR, Jiang Y, et al. The utility of proadrenomedullin and procalcitonin in comparison to C-reactive protein as predictors of sepsis and bloodstream infections in critically ill patients with cancer. Crit Care Med. 2014; 42: 2500-2507. doi: 10.1097/CCM. 0000000000000526 PMID: 25083975
28. Oliveira CF, Botoni FA, Oliveira CR, Silva CB, Pereira HA, Serufo JC, et al. Procalcitonin versus Creactive protein for guiding antibiotic therapy in sepsis: a randomized trial. Crit Care Med. 2013; 41: 2336-2343. doi: 10.1097/CCM.0b013e31828e969f PMID: 23921272
29. Devran O, Karakurt Z, Adiguzel N, Gungor G, Mocin OY, Balci MK, et al. C-reactive protein as a predictor of mortality in patients affected with severe sepsis in intensive care unit. Multidiscip Respir Med. 2012; 7: 47. doi: 10.1186/2049-6958-7-47 PMID: 23171626
30. Jain S, Sinha S, Sharma SK, Samantaray JC, Aggrawal P, Vikram NK, et al. Procalcitonin as a prognostic marker for sepsis: a prospective observational study. BMC Res Notes. 2014; 7: 458. doi: 10.1186/1756-0500-7-458 PMID: 25034373
31. Robinson JO, Lamoth F, Bally F, Knaup M, Calandra T, Marchetti O. Monitoring procalcitonin in febrile neutropenia: what is its utility for initial diagnosis of infection and reassessment in persistent fever? PLoS One. 2011; 6: e18886. doi: 10.1371/journal.pone.0018886 PMID: 21541027